Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence

Fig. 6

P-A sequence specifically increased the accumulation of pemetrexed in tumor mass. A Pharmacokinetic profiles of pemetrexed and aumolertinib in plasma of H1975 and HCC827 tumor bearing mice in the absence and presence of sequence administration were plotted, respective (n = 4). B The concentrations of pemetrexed and aumolertinib in H1975 and HCC827 tumor xenograft at 4 h post drug administration were assayed (n = 5). Con represents control; P represents pemetrexed; A represents aumolertinib; Osi represents osimertinib; P-A represents pemetrexed treatment followed by aumolertinib treatment. All of the data were expressed as the mean ± SEM, * p < 0.05 and *** p < 0.001

Back to article page